| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
| deletion
|
|
|
|
in breast carcinoma (expression was inversely correlated with tumor stage but not with tumor grade or lymph node status |
| tumoral
|
|
|
| loss of function
|
|
by hypermethylation in colorectal cancer and in ovarian cancers |
| tumoral
|
|
|
| loss of function
|
|
by hypermethylation in non-small-cell lung cancer (NSCLC) |
| tumoral
|
|
|
| loss of function
|
|
by promoter hypermethylation, predominant mechanism of SFRP1 gene silencing in breast cancer and is associated with unfavourable prognosis |
| tumoral
|
|
| --low
|
|
in transitional cell carcinomas of the bladder  |
| tumoral
|
|
| --low
|
|
|
silencing leads to oncogenic activation of the Wnt pathway and contributes to cervical cancer progression through the epithelial mesenchymal transition program |
| tumoral
|
|
| --low
|
|
|
markedly reduced in both the breast cancer cell lines and primary tumour specimens relative to normal primary mammary epithelial cells even when SFRP1 is amplified |
| tumoral
|
|
| --low
|
|
|
by hypermethylation in primary hepatocellular carcinoma |
| tumoral
|
|
| --low
|
|
|
methylation-associated silencing of SFRP1 frequently occurs in renal cell carcinoma and plays a pivotal role in early carcinogenesis |
| tumoral
|
|
| --low
|
|
|
by promoter methylation frequently found in renal cell carcinoma |
| constitutional
|
|
|
| loss of function
|
|
of SFRP1 and SFRP2, two postulated Wnt antagonists, perturbs retinal neurogenesis |
| constitutional
|
|
| --low
|
|
|
by hypermethylation in keloid tissues, compared with that in normal skin tissues |
| tumoral
|
|
| --low
|
|
|
decreased markedly in patients with acute myeloid leukemia (AML) compared to controls |
| constitutional
|
|
| --low
|
|
|
of SFRP1 may contribute to the pathogenesis of IUGR placental dysfunction, whereas the loss of the protein may be involved in the development of human trophoblastic tumors |
